Anti-hepatitis B Virus X Protein in Sera is One of the Markers of Development of Liver Cirrhosis and Liver Cancer Mediated by HBV.

Hang Zhang,Lian-Ying Wu,Shuai Zhang,Li-Yan Qiu,Nan Li,Xuan Zhang,Xue-Zhi Zhang,Chang-Liang Shan,Li-Hong Ye,Xiao-Dong Zhang
DOI: https://doi.org/10.1155/2009/289068
2009-01-01
BioMed Research International
Abstract:Hepatitis B virus X protein (HBx) plays a crucial role in the development of hepatocellular carcinoma (HCC). However, the significance of circulating antibody to hepatitis B virus X antigen (anti-HBx) in sera remains unclear. In the present study, we examined the titers of anti-HBx (IgG) in the sera from 173 patients with chronic hepatitis B (CHB), 106 liver cirrhosis (LC), and 61 HCC by enzyme-linked immunosorbent assay (ELISA), respectively. Our data showed that the positive rates of anti-HBx were higher in sera of LC (40.6%) and HCC (34.4%) than those of CHB (10.4%), P < .05. In all 40 patients with anti-HBx+ out of 340 patients, 39 (97.5%) were HBsAg/HBeAg/anti-HBc+ and 1 (2.5%) was anti-HBs+ (P < .01), suggesting that anti-HBx in sera is a marker of HBV replication rather than a protective antibody. Thus, our findings reveal that circulating anti-HBx in sera is one of the markers of development of LC and HCC mediated by HBV.
What problem does this paper attempt to address?